OncoMatch/Clinical Trials/NCT06685887

A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis

Is NCT06685887 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including HIPEC and SOX for gastric cancer.

Phase 2RecruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT06685887Data as of May 2026

Treatment: HIPEC · SOX · Immune Checkpoint Inhibitors — This study is a single-center, prospective, phase II clinical trial aimed at assessing the impact of HIPEC combined with systemic chemotherapy and immune checkpoint inhibitors on the R0 resection rate in patients with peritoneal metastasis from gastric cancer. Furthermore, it seeks to analyze the effects of this treatment strategy on overall survival (OS), progression-free survival (PFS), PCI and adverse reaction rates.

Check if I qualify

Extracted eligibility criteria

Cancer type

Gastric Cancer

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: radiation therapy

Cannot have received: chemotherapy

Cannot have received: targeted therapy

Cannot have received: immunotherapy

Lab requirements

Blood counts

HB ≥ 90 g/L; ANC ≥ 1.5×10^9/L; plt ≥ 125×10^9/L

Kidney function

Cr ≤ 1.25ULN

Liver function

TBIL < 1.5ULN; ALT, AST < 2.5ULN; ALB ≥ 30 g/L

Normal major organ function: 1) HB ≥ 90 g/L； ANC ≥ 1.5×10^9/L; plt ≥125×10^9/L; 2) TBIL<1.5ULN; ALT, AST <2.5ULN; Cr≤1.25ULN; ALB ≥ 30 g/L

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify